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Mucosal Immunology in the 
Inflammatory Bowel Diseases
Giovanna Rosa Degasperi
Abstract
Inflammatory bowel disease (IBD) includes two major phenotypes, Crohn’s dis-
ease and ulcerative colitis, which have different clinical characteristics and immune 
response profiles. Dysregulation of the intestinal immune response with elevated 
secretion of proinflammatory cytokines is a hallmark of IBD. In this chapter, we 
will characterize the cells of the innate and adaptive immunity involved in the 
pathogenesis of IBD. Innate lymphoid cells as well as dendritic cells, neutrophils, 
macrophages, B cells and T cells, including Th1 and Th2, Th9 and Th17 cells will be 
specifically characterized in this scenario. The cross talks and cytokine-mediated 
regulation of these cells with emphasis on cytokines IL-17, IL-22 and IL-23 will also 
be emphasized.
Keywords: inflammatory bowel disease, innate immune response, adaptive immune 
response, T regulatory cells, toll-like receptors
1. Introduction
Inflammatory bowel disease has become a worldwide health burden with 
increasing incidence and prevalence, contributing to the increased risk of colorectal 
cancer development [1]. IBD encompasses both Crohn’s disease (CD) and ulcerative 
colitis (UC). Its etiopathology is still unknown, although it is believed that it may be 
a combination of genetic and environmental factors, as well as microbiota, diet and 
immune response.
Evidence suggests that abnormalities in both the innate and adaptive immune 
responses against intestinal microbiota, harmful antigens or extrinsic pathogens 
which may have crossed the intestinal barrier play an important role in the inflam-
matory process associated with the disease in genetically susceptible individuals. 
Several components of the mucosal immune system are implicated in the patho-
genesis of IBD, including innate lymphoid cells, innate immune response (macro-
phages, neutrophils, and dendritic cells), and adaptive immune response (T and B 
cells) cells, as well as different cytokine and chemokine types which are secreted by 
these cells [2].
TCD4+ lymphocytes from the intestinal mucosa, through the production of 
pro-inflammatory cytokines, play a central role both in the induction and in the 
persistence of chronic inflammation which are characteristic of CD and UC. These 
cells are key components of the adaptive immune response able to secrete specific 
cytokines in response to the recognition of peptides in MHC Class II in antigen-
presenting cells (ACP), several cytokines and the expression of transition factors, 
in a process known as differentiation of TCD4+ or Th0 cells, which results in the 
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generation of T helper lymphocytes (Th) Th1, Th2, Th17, and Th9. These cells have 
the peculiarity of secreting specific cytokines. These subsets of differentiated T 
helper lymphocytes perform a number of functions. However, immune responses 
executed in a dysregulated manner by some of these subsets result in chronic 
inflammation and tissue damage [3].
In the intestinal mucosa, APCs such as dendritic cells can induce differentiation 
of naïve TCD4+ lymphocytes in one of the specific subsets of T helper which will 
be responsible for altering intestinal homeostasis, contributing to the setting in 
of chronic inflammation in the intestine which is a hallmark of IBD. While CD is 
mediated by Th1 cells, UC has been identified as a disease associated to Th2 cells. 
Studies indicate that, in CD, the Th1-related cytokines, such as the tumoral necrosis 
factor α (TNF-α), interferon-γ (IFN-γ), interleukin-12 (IL-12), as well as those 
associated to Th17 such as IL-17A, IL-21, and IL-23, are increased in the intestinal 
mucosa [4]. In UC, it has been demonstrated that there is an increase in the produc-
tion of IL-5 and IL-13 which are Th2 identity cytokine [5].
In addition to Th17 cells, IL-9-secreting Th9 cells can also promote exacerbate 
inflammatory diseases such as IBD [6, 7]. Th9 cells are also known to be involved 
in immunity against helminth parasites [8]. Moreover, results from colitis animal 
models and studies in humans indicate a role for innate lymphoid cells (ILC) in the 
pathogenesis of chronic intestinal inflammation in IBD. The ILC are a population of 
lymphocytes present in regions of the mucosa, in which they perform the function 
of protecting against pathogens, including extracellular bacteria, helminths, and 
viruses. The ILCs are cells with a high degree of plasticity depending on the exposi-
tion to cytokines from the microenvironment in which they are present.
2.  General features of the colon mucosal: barriers of protection and 
intestinal immune system
The intestinal epithelium has important functions, such as absorption, secretion 
and digestion. In the epithelium, in addition to enterocytes, some other epithelial 
cells, such as goblet cells, perform a protective function through the secretion of 
mucus. This protective action may be verified in experiments with animal models 
which show that MUC2-null mice developed spontaneous colitis [9]. In addi-
tion to goblet cells, Paneth cells also display protective action, since they produce 
defensins, which are antimicrobial peptides that modulate the composition of the 
intestinal microbiota [10].
The epithelium forms a mucous barrier with tight junctions between the entero-
cytes preventing the entrance of a myriad of substances. Defects in the epithelial 
integrity may contribute to the development of IBD, allowing the passage of 
microorganisms through the epithelial layer. In chronic inflammatory disorders, 
such as IBD, the microbial components of the microbiota are translocated through 
the damaged barrier of the mucosa and, through the interaction with cells of the 
immune system in the lamina propria, trigger an inflammatory response [11].
The intestinal epithelium is located between the lumen and the lamina propria. 
In the lamina propria there are cells of the immune system, and, in the lumen, the 
microbiota consists of commensal microorganisms, including bacteria, viruses 
and fungi. The most abundant cells in the epithelial compartment are absorptive 
cells, which not only provide a physical barrier against luminal antigens, but also 
mediate the crosstalk between the intestinal microbiome and the immune system 
of the host, particularly through the innate immune receptors, specifically, the 
pattern recognition receptors (PRR), known as Toll-like receptors (TLR), which 
are expressed throughout the intestinal tract. The healthy human small intestine 
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expresses TLR-2 and TLR-4 [12]. Cells of the innate immune compartment which 
reside in the lamina propria are sentinels which detect invading pathogens through 
their TLR. These cells are part of the mononuclear phagocytic system, including 
macrophages and dendritic cells which encompass and process microbial antigens 
in the naïve TCD4+ lymphocytes from Peyer’s patches, through major histocom-
patibility complex type II (MHC II). The TCD4+ lymphocytes produce cytokines 
which activate B cells into transforming into plasmocytes which selectively produce 
immunoglobulin A (IgA).
The IgA is an abundant isotype in blood serum, in which it is normally pres-
ent in concentrations of 1 to 3 mg/ml. In circulation, IgA is generally found as a 
monomer IgA [13, 14]. Dimeric IgA is the predominant antibody in secretions 
of the gastrointestinal tract. In this format, IgA is generated by the union of two 
molecules of monomeric IgA. Its production is mediated by the plasmocytes located 
in the lamina propria of the mucosa, and, despite being a protein, IgA present in the 
secretions of the lumen is quite resistant to proteolysis by the gastric and intestinal 
enzymes [15].
The process of transport and secretion of this immunoglobulin of the plasmo-
cytes located in the lamina propria from the mucosa to the intestinal lumen occurs 
through the connection to receptors for immunoglobulins which are expressed in 
the mucosal epithelial cells’ basal layer. Once the connection is made, the complex 
formed is endocytosed by the epithelial cell and transported to the apical portion 
of the cell membrane, where it is then liberated in the lumen with the extracellular 
fragment of the receptor, thus forming secretory IgA (sIgA) [16].
In the lumen, these IgA have the capacity to connect to antigens from the 
mucosa surface, preventing their penetration and adherence to the epithelial layer 
of the mucosa. The formation of the antigen-sIgA complex favors the retention of 
pathogenic microorganisms to the mucus and stimulates its secretion, facilitating 
the enzymatic degradation and antigen elimination without having to activate the 
inflammatory response [17].
In patients with IBD, the damage of the barrier function of the intestinal 
epithelial layer results in an influx of IgA-opsonized bacteria. Interestingly, it has 
been demonstrated that the presence of these immune IgA complexes in the lamina 
propria contributes to inflammation induced by FcαRI [13]. Recent findings have 
demonstrated that co-stimulation of FcαRI strongly affects pro-inflammatory 
cytokine production by some immune system cells such as phagocytes. FcαRI is also 
expressed in immune cells such as eosinophils and dendritic cells [18].
Thus, there is ample evidence of defense against intestinal pathogens. The 
epithelial layer, mucus, antimicrobial peptides, immune system cells in the lamina 
propria, and IgA together help to establish a beneficial environment to tolerate the 
diverse community of bacteria of the microbiota and food antigens, as well as to 
elaborate a response against pathogenic microorganisms.
3. TLRS: key immune sensors of microbiota in the gut
Throughout the gastrointestinal mucosa there are receptors which specialize in 
identifying pathogenic microorganisms. The process of recognition of pathogens 
is highly specific and occurs through the connection between pathogen-associated 
molecular patters (PAMP) and PRR. Known PRR are classified as: TLR, NOD-like 
receptors (NLR), RIG-1-like receptors (RLR), of which the TLR are the most cor-
related to IBD.
In mammals, TLR comprise a family of 13 types of receptors, of which TLR 1–9 
are more easily found in cells from the small and large intestines. In humans, only 
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TLR 2, 3, 4, 5, and 9 have been consistently identified, highlighting that TLR-3 and 
TLR-5 are present in larger numbers in the enterocytes. The TLR are found in the 
plasma membrane or in the endosomal intracellular compartments. The activa-
tion of these receptors is made by PAMP which have relative specificity to distinct 
TLR. The TLR-2, for example, identifies peptidoglycans and lipoproteins; TLR-3 
identifies viral RNA; TLR-4 recognizes lipopolysaccharide (LPS); TLR-5 recognizes 
flagellin, and TLR-9 connects to bacterial DNA. Despite the small number of recep-
tors, this distribution reflects the elevated capacity for identifying molecular patters 
in a number of pathogens [19].
Once activated, TLR become dimerized and trigger the subsequent activation 
of downstream signaling cascades, e.g., the activation of NF-κB which leads to 
the induction of a variety of inflammatory cytokines. Except for TLR3, other TLR 
signaling pathways depend on MyD88 to activate NF-κB and produce pro-inflam-
matory cytokines. The TLR signaling pathway is quite similar to the interleukin 
(IL)-1R family, since TLR contains the domain Toll/Interleukin-1 (TIR). The TIR 
domain contains the TIRAP adaptor protein. When TLR-1, 2 or 6 are activated, the 
domain containing TIRAP lying downstream of these TLR and recruits the adaptor 
protein from the primary myeloid response 88 (MyD88) which leads to the activa-
tion of the kinase associated with the IL-1 receptor (IRAK). The activation of IRAK, 
in turn, induces the activation of serine and threonine kinases which are responsible 
for the degrading of IκBα, known as an inhibitor of the nuclear transcription factor 
κB or NF-κB. The degrading of IκBα allows for the migration of the NF-κB from 
cytoplasm to the nucleus. In the nucleus, this nuclear factor induces the production 
of pro-inflammatory cytokines and chemokines which will trigger the innate and, 
subsequently, the adaptive immune responses [20].
Furthermore, there is an alternate signaling pathway to MyD88 which involves 
TLR-3 and TLR-4. This alternate pathway is mediated by the activation of the TIR-
domain-containing adapter-inducing Interferon-β (TRIF). Thus, signaling TLR 
is divided in two pathways: one dependent on MyD88 and the other independent 
of MyD88, but dependent on TRIF. Downstream of the TLR signaling pathways, 
activated NF-κB and interferon regulatory factor (IRF) to the production of pro-
inflammatory cytokines [20].
Additionally, TLRs provides a connection between innate and adaptive immu-
nity. Dendritic cells that is innate immune response cell, can sense microbes by 
these receptors in their surface. In this way, this cell controls microbial driven 
T lymphocyte polarization to Th1, Th2, Th9 or Th17 in lymphoid tissues. After 
interaction with microbial components, immature dendritic cell migrate to the 
draining lymphoid tissues to present microbial antigens to T lymphocytes [21]. It 
was hypothesized that an abnormal pattern of bacterial recognition by these cells 
through TLRs alter its activation and cytokine production which may underlie 
chronic inflammatory processes, such as IBD [22].
A number of studies have shown a correlation between TLR and IBD, be it 
enabling or inhibiting the disease. Interestingly, it has been demonstrated that 
TLR-2 must form heterodimers with TLR1 or TLR6 in order to trigger intracellular 
signaling pathways. The inhibition of TLR2/6 signaling has played a beneficial 
role by slowing down IBD progression. It was also reported that TLR6 was overex-
pressed in the intestines of IBD patients and might promote experimental colitis 
in mice [23]. In this case, it was proved that TLR-6 was important and activated 
the polarization of Th1 and Th17 of TCD4+ lymphocytes. Also, considering that 
TLR4 gene expression was upregulated in the intestinal epithelia of patients with 
active UC, TLR4 might be a participant in UC disease development. Moreover, it 
was demonstrated that TLR8 is upregulated in patients with active UC and that the 
expression of the genes TLR2, 4, 8 and 9 is positively regulated in these patients. 
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Contrary to the evidence presented above, which show TLR supporting IBD, studies 
show that the activation of TLR-9 prevented the development of inflammation of 
the mucosa, and fomented healing of wounds in models of colitis [24]. Still others 
presented data that TLR3, TLR7, or TLR9 agonists could induce type I IFN, which 
can prevent experimental colitis [25].
4.  The link between innate and adaptive immune response in intestine: 
the role of macrophages and dendritic cells
Macrophages and intestinal dendritic cells which reside in the lamina propria are 
APCs that act as sentinels to the maintenance of intestinal homeostasis. They are 
capable of establishing an interaction between the innate and adaptive immunity by 
means of the presentation of antigens to the naïve TCD4+, via MHC II [26].
The recognition of microorganisms for phagocytosis occurs by means of 
PRR. Macrophages also express PRR which recognize PAMP present on the surface 
of invading intestinal microorganisms. It is through this interaction that immune 
cells distinguish between commensal microorganisms and pathogens, thus design-
ing an appropriate immune response program. Captured antigens from pathogenic 
microorganisms are presented to naïve TCD4+ lymphocytes via MHC class II. In 
1998, it was described that intestinal macrophages in mice carrying colitis present 
low levels of MHC class II expression, which hinder adaptive immune response in 
the inflammatory condition established by this disease [27].
With relation to dendritic cells, they also have the function of transporting anti-
gens to mesenteric lymph nodes and Peyer’s patches, and, subsequently, inducing 
the generation of responses by intestinal TCD4+ lymphocytes specific to the anti-
gen. They act as sentinels, acquiring antigens in peripheral tissues before migrating 
to secondary lymphoid organs. Dendritic cells can recognize antigens through the 
emission of their extensions in the luminal region. Alternatively, this recognition 
may occur through M cells which are also considered as presenting antigens. The M 
cells can recognize antigens in the intestinal lumen, internalize them and present 
them to the dendritic cells located in the lamina propria of the mucosa [28, 29].
Dendritic cells and macrophages are characterized according to their expression 
of specific membrane markers [30]. The intestinal dendritic cells may be divided in 
CD103+CD11b+ and CD103+CD11b− in mice, or CD103+Sirpα+ and CD103+Sirpα− in 
humans [31]. Dendritic cells, both in mice and humans, stimulate the differentia-
tion of Th1 and Th17 lymphocytes subtypes [32]. Regarding intestinal macrophages, 
they are identified by their expression of the F4/80, CD64, CD11b and CX3CR1 
markers [33, 34]. In these macrophages, despite their ample phagocytic activity, the 
expression of co-stimulatory molecules CD40, CD80 and CD86 are decreased, as 
well as innate immune response receptors such as LPS or CR3 [35, 36].
Macrophages residing in the lamina may still be differentiated in two distinct 
phenotypes characterized as M1 and M2. Specific combinations of cytokines induce 
the polarization to one of these phenotypes. IFN-γ induces the appearance of the 
M1 phenotype, which has as its identity the secretion of TNF-α, IL-12, IL-6 and 
IL-23 pro-inflammatory cytokines. These cytokines are present in the context of 
inflammatory intestinal diseases. The M2 macrophages arise in microenvironments 
rich in IL-4 and produce large quantities of IL-10 [37]. It is known that mice defi-
cient in IL-10 develop spontaneous colitis [38]. Moreover, mutations in genes which 
codify proteins in the IL10R subunit have been found in patients with early-onset 
enterocolitis [39]. Generally, while M1 macrophages cause tissue damage and hinder 
cell proliferation, M2 macrophages support proliferation and tissue repair [40]. It 
was shown that M1 macrophages which invade intestinal tissues contribute directly 
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to break the epithelial barrier by means of disruption of tight junction proteins and 
induction of apoptosis of epithelial cells, thus supporting intestinal inflammation 
which is characteristic of IBD [41].
While mononuclear phagocytes perform an important role in the induction of 
inflammation in several tissues by means of the production of pro-inflammatory 
cytokines, chemokines and oxygen-free radicals, residing macrophages as well as 
intestinal dendritic cells exhibit a tolerogenic phenotype mediating tolerance to 
commensal microorganisms [42, 43].
Thus, macrophages phagocyte intestinal pathogens efficiently, although they do 
not cause an exacerbated inflammatory response. This is a characteristic which dis-
tinguishes intestinal macrophages from those found in other compartments. When 
macrophages present disorders in the recognizing microorganisms in the intestine, 
an inflammatory reaction may be established. This condition has been observed in 
IBD. In such situations, these macrophages produce high, significant quantities of 
IL-1β, IL-6, TNF-α and IL-23 [44]. Among them, IL-23 can stimulate the production 
of IL-22 under several infectious conditions [45]. IL-22 is essential for preventing 
the integrity of the intestinal barrier and inducing the production of antimicrobial 
peptides and chemokines which recruit cells such as, e. g., neutrophils [46].
5. Old and new lymphocyte players in inflammatory bowel disease
5.1 Revisiting TH1 and TH2 lymphocytes
Naïve TCD4+ lymphocytes have a high degree of plasticity and the capacity for 
differentiating into subsets of effector or regulatory T cells during the process of 
activation. For approximately two decades, it was believed that these lymphocytes 
could only divide into the subtypes Th1 or Th2 [47].
The effector T lymphocytes subtypes Th1/Th2 were the first to be described in 
scholarly literature, leading to the comprehension of how TCD4+ could shape the 
appropriate response to different pathogens. Subsequently, the identification of 
effector T lymphocytes Th17, T regulatory (Treg) and Th9 changed the Th1/Th2 
historical paradigm.
These subtypes express distinct factors of transcription and secret different 
cytokines. In response to antigenic stimuli, TCD4+ lymphocytes express transcrip-
tion factors which determine specific signaling pathways. These are responsible 
for the production of cytokines to each of these T cell patterns. The differentiation 
to a particular type of effector T lymphocytes is intimately related to interleukins 
which are available in the microenvironment in which a naïve TCD4+ lymphocytes 
is exposed. Th1 cells have as signature the production of IFN-γ, TNF-α and IL-12, 
which are responsible for cellular immunity and host defense against a number 
of pathogens, especially intracellular organisms. Interleukin-12 acting via the 
transcription factor STAT4, in concert with another transcription factor, T-bet, 
are critical for Th1 differentiation. On the contrary, the development of Th2 cells 
is initiated by the signaling of IL-4 with a participation of the STAT6 and GATA3 
transcription factors. Classically, the Th2 lineage is specialized in the elimination of 
parasitic infections (such as helminths). IL-4, along with IL-5 and IL-13 produced 
by this lineage, are potent activators of B cells which, in this condition, produce IgE 
immunoglobulin and recruit eosinophils [48].
CD is a disease mediated by Th1, while it is believed that UC is mediated by 
Th2 response. A significant increase of Th1 cytokines has been demonstrated 
in inflamed mucosa of CD, whereas the in inflamed areas of UC as increased 
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cytokines were present in a Th2 profile [49]. Another study showed that the T cells 
in the mucosa of DC patients secret high amounts of IFN-γ and IL-2 than from 
T-lymphocytes from UC patients [50, 51]. Furthermore, it has been demonstrated 
that UC patients produce increased amounts of IL-5 [52]. Data from biopsies of 
both DC and UC patients showed high ex vivo levels of IFN-γ and lower levels 
of IL-13 have been found in UC as compared to DC patients [53]. In addition, 
it has been demonstrated that IL-5, IL-13, IL-15 and IL-33 mRNA levels in DC 
patients were significantly increased when compared to both DC and control [5]. 
Interestingly, it was shown that pediatric CD is characterized by Th1 in the terminal 
ileum and Th1/Th17 immune response in the colon [54]. However, currently it is 
considered that Th1 and Th2 immune responses do not represent the complexity 
of immune responses measured by intestinal T cells. In such a context, as will be 
discussed in the next section, more recent studies have demonstrated the involve-
ment of the Th17 pathway in the physiopathological processes of IBD [55].
5.2 TH17: friend and foe
Studies suggest that Th17 cells perform an important role in the host’s defense 
against extracellular pathogens which are not effectively countered by Th1 or Th2 
cells. They are also known by their action in the physiopathology of autoimmune 
diseases and recently have been identified in the scenario of IBD.
Th17 cells require specific cytokines and transcription factors for their differ-
entiation. They are dependent on IL-6 and TGF-β for their differentiation and are 
defined by expression of the transcription factor RORγt orphan nuclear receptor 
[56]. Interestingly, in the absence of IL-6, the cytokine TGF-β promotes the dif-
ferentiation of FoxP3 innate regulatory T cells (iTreg). The expression of IL-23R 
is low in naïve T lymphocytes, although, in the presence of IL-6 and TGF-β, there 
is an increase in the expression of the IL-23 receptor. IL-23 is not necessary for the 
appearance of the Th17 phenotype, although it is important for its maintenance and 
expansion [57]. The signaling of TGF-β hinders IL-23R and antagonizes RORyt, 
contributing also to the appearance of iTreg [58].
Signal transduction downstream of IL-6 and TGF-β, including JAK/STAT3 
activation, induces expression of RORγt, which is the master transcription factor 
defining Th17 cells as a distinct lineage and promotes transcription of IL-17. The 
cytokines produced belong to the IL-17 family and are known as IL-17A (com-
monly known as IL-17), IL-17B, IL-17C, IL-17D, IL-17E (or IL-25) and IL-17F [57]. 
Cytokines are characterized as pro-inflammatory if they induce the recruitment 
of neutrophils. However, Th17 cells are also capable of secreting IL-21 and IL-22, 
which perform the important role of host defense on the mucosa surface as well 
as acting against extracellular pathogens, such as fungi and bacteria. In addition 
to Th17 cells, others have been characterized as secreting IL-17 and IL-22, such as 
innate lymphoid cells (ILCs), natural killer cells, NKT cells, mast cells, as well as 
phagocytes that are recruited to the site of infection [59].
Some evidence show that interleukins IL-17 and IL-22 may perform a protective 
function by inducing the production of antimicrobial peptides, as well as acting 
in the recruitment of neutrophils to act in the defense against fungi and bacteria 
[60–62]. It is known that in intestinal epithelial cells IL-17 stimulates the expression 
of tight junction claudin proteins [63]. In an experimental animal model of dextran 
sulfate sodium (DSS)-induced colitis, it was demonstrated that IL-17 regulates the 
localization of the tight junction protein occludin and also reduces gut permeability 
following epithelial injury [64]. In the IBD scenario, Th17 cells appear as protago-
nists in the inflammatory process [65]. It was demonstrated that IL17R knockout 
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mice were protected against the induction of colitis by trinitrobenzenesulfonic acid 
(TNBS). In another study, a high expression of IL-17A was reported in blood serum 
and in the colon of IBD patients [66]. Other groups indicated a positive correla-
tion between the severity of the disease and the levels of IL-17 in ulcerative colitis 
patients, or even that lymphocytes which produce IL-17 and IL-23 were increased in 
colitis and DC patients [67].
Thus, this protector role contradicts the pro-inflammatory role of Th17 cells 
in IBD and the distinguishing factor between beneficent and pathogenic Th17 is 
still unclear. Additional studies are required to clarify if Th17 lymphocytes at any 
moment lose this protecting role in the course of IBD or if the inflammatory role in 
these diseases is due to a Th17 pro-inflammatory cell response which is boosted by 
recently activated naïve TCD4+ lymphocytes.
5.3  T regulatory cells in maintaining homeostasis at the intestinal  
lamina propria
Two types of Tregs cells are well characterized in the literature such as natural 
Tregs (nTregs) cells which are generated in the thymus through IL-2 signaling and 
as induced or adaptive Tregs (iTregs) arising in peripheral tissues [68, 69]. The key 
cytokine for the induction of Treg cells, especially the iTregs, is the TGF-β and the 
FOXP3 transcription factor is considered as an identity and the main regulator for 
the differentiation and function of these cells [69]. Treg cells produce IL-10 and 
themselves also produce large amounts of TGF-β.
These cells play a role in maintaining peripheral tolerance to their own antigens 
[70]. In the intestinal lamina propria they are important for the maintenance of tis-
sue homeostasis through the negative regulation of T effector cells (Teff cells). This 
regulation occurs through the production of the immunosuppressive cytokine IL-10 
and the expression of CTLA-4, which is able to deplete CD80/CD86 [71]. The CD80 
and CD86 expressed by APCs provide essential co-stimulatory signals to T lympho-
cytes through ligation of CD28 in addition to T cell receptor (TCR) signaling [72]. 
CTLA-4 also appears to play a particularly important immunoregulatory role in the 
human intestine. It has been shown that treatment with anti-CTLA-4 Ipilimumab 
for cancer, increases the immune response against the disease by decreasing Treg cell 
function. However, data shows that this treatment can result in potentially lethal 
colitis in a number of patients [73, 74].
Abnormalities in the functions as well as the presence of these cells in the 
intestine contribute to the establishment of IBD [75, 76]. The inhibitory molecule 
CTLA-4 is highly expressed on the surface of Treg cells and plays a critical role in the 
inhibitory function both in vitro and in vivo of Treg cells by limiting availability of 
CD80 and CD86 (Slavik et al., 1996). CD80 and CD86 expressed by APCs supply 
essential co-stimulatory signals to T cells via ligation of CD28 in addition to TCR 
signaling [77].
Inflammation in IBD may occur as a function of an imbalance between Th17 
cells and Treg cells. It is known that both Th17 and iTregs are from TCD4+ lympho-
cytes in the presence of TGF-β. However, when IL-6 cytokine levels are elevated in 
the gut, TGF-β and TCR signaling result in upregulation of RORγt and therefore in 
the appearance of Th17 cells with pro-inflammatory profile. As discussed above, the 
role of lymphocytes in IBD is unclear. Several studies have shown them to be either 
pathogenic or protective [78].
A decrease in Treg and increase in Th17 cells was observed in the peripheral blood 
of IBD patients [79]. Additionally, the ability of Treg cells to suppress autologous 
T-cell proliferation was reduced in IBD patients [80].
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5.4 TH9: new lymphocyte players in IBD
In addition to the previously discussed T lymphocyte subtypes Th1, Th2 and 
Th17, studies have confirmed the existence of a new one denominated Th9, which 
are characterized by the expression of high amounts of IL-9. Initially, it was 
believed that IL-9 was produced by the Th2 subtype; however, it has been discov-
ered that Th9 lymphocytes do not express the GATA-3 transcription factor in com-
parable levels to the Th2 lymphocyte, and not even other transcription factor, such 
as T-bet, RORγt and FOXP-3, characteristic of Th1, Th17 and Treg, respectively.
Naïve T cells differentiate into Th9 if they are exposed simultaneously to IL-4 
and TGF-β. The transcription factor STAT6 protein, activated by IL-4, stimulates an 
increase of IL-9 in Th9 cells [81]. Interestingly, it was shown that IL-4 and STAT6 
are responsible for downregulating Treg cells by the inhibition of FOXP3 expression, 
which results IL-9 production [82].
Still, a complicated network of transcription factors, such as Interferon 4 (IRF4) 
regulating factor and Smads are essential to adequate induction of this phenotype. 
Additionally, PU.1 transcription factor is critically involved in the signaling medi-
ated by TGF-β. TGF-β is also important to the signaling pathways which culminate 
in the activation of Smad2, Smad3 and Smad4 transcription factors, which are 
necessary to appearance of the Th9 phenotype [83].
Several experimental pieces of evidence suggest that Th9 cells are involved in 
the pathogenesis of IBD. It has been demonstrated that mice which received in vitro 
cultivated T cells with TGF-β and IL-4 developed severe colitis [84]. Nalleweg et al. 
investigated the expression of IL-9 and IL-9R in peripheral blood, biopsies and 
surgical samples from patients with ulcerative colitis. Among other results, they 
showed that mRNA expression was significantly increased in inflamed samples 
from these patients. Additionally, it was shown that IL-9R was overexpressed on 
gut epithelial cells and IL-9 induced STAT5 activation in these cells. Considering 
the results, it was suggested that targeting IL-9 might become a therapeutic option 
for patients with ulcerative colitis also suggest that Th9 cells represent a likely target 
for the treatment of chronic intestinal inflammation [85]. The authors found that in 
patients with ulcerative colitis are more T cells expressing the transcription factor 
PU.1 and interleukin 9 (IL-9). In this study, the mice whose T cells were deficient in 
PU.1 were protected from colitis, which was even suppressed when these animals 
were treated with antibody to IL-9.
Additionally, a study which analyzed IL-9 in venous blood samples de CD and 
UC patients, it became evident that there was a significant correlation between 
disease severity and IL-9 in the CD patients, but not in the UC [86].
Th9 cells also regulate the intestinal mucosa’s barrier function. The exacerbated 
intestinal IL-9 production breaks the intestinal epithelial barrier and compromises 
tolerance to certain commensal microorganisms, which enables the occurrence 
of inflammation. In an animal experimental model of TNBS-induced colitis, the 
expression of tight junction molecules was investigated in the inflamed colon. It was 
observed that some of these molecules were up regulated in the colon of TNBS-
treated IL-9 KO mice [87].
6.  Innate lymphoid cells (ILCS): innate counterparts of T-helper 
lymphocytes
A decade after their discovery, ILCs are currently recognized as perform-
ing a regulator function of intestinal homeostasis, and alterations in these cells’ 
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responses are related to IBD [88]. They represent a family of immune system cells 
which derive from a progenitor known as Id2 and process the morphologic charac-
teristics of lymphocytes, although they do not have rearrangements at the antigen 
receptors. The cells of these groups are able to produce cytokines which correspond 
to the profile of those produced by the TCD4+ subtypes [89]. ILC are categorized in 
three groups, detailed bellow.
Group 1 ILC are comprised of ILC1 and natural killer cells. The Tbet transcrip-
tion factor and the IL-12, IL-15 and IL-18 cytokines are responsible for the genera-
tion of these cells which have as a characteristic the production of Th1 cytokines, 
particularly IFN-γ [90]. The cells in the Group 02 are characterized as ILC-2 and are 
dependent on GATA and RORyt transcription factor, as well as the stimulus of IL-25 
and IL-33 cytokines. These cells produce Th2 cytokines, such as IL-5 and IL-13 [91]. 
In Group 3, ILC3 and lymphoid tissue inducer (LTi) cells are RORyt dependent, 
and, similarly to Th17, have the ability of secreting IL-17 and IL-22 through the 
same stimulus with IL-1β and IL-23 [92]. ILC3 are the most abundant in the gastro-
intestinal tract [93, 94].
The ILC3, in the intestine, in addition to interacting directly with the microbi-
ota, act together with other cells to ensure and maintain local homeostasis. Studies 
have revealed that ILC of this group express MHC II and can process and present 
antigens. However, when in contact with TCD4+ lymphocytes by MHC II, instead 
of inducing the proliferation of these cells, the ILC act by limiting the response 
theses lymphocytes to commensal bacteria. It has been demonstrated that, in the 
Figure 1. 
During intestinal inflammation, such as IBD, barrier permeability is impaired, allowing the passage of 
luminal antigens into the lamina propria. These antigens can be recognize by TLR or captured by M cells. The 
exposure of immune cells to the luminal content induces TCD4+ activation, differentiation and inflammatory 
cytokine release as well as neutrophil recruitment. IgA-opsonized bacteria contributes to the inflammation 
induced by FcαRI. Several environmental factors (diet, genetics, lifestyle) can modulate the microbiota 
composition and the activation of immune cells in the gut. UC, Ulcerative Colitis; DC, Crohn’s Disease; ILCs, 
Innate Lymphoid Cells, Th, T helper cells; Targ, T Regulatory Cells, IgA, Immunoglobulin A; sIgA, Secretory 
IgA, TLR, Toll Like Receptor; FcαRI, FcαReceptor I.
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absence of MHC II, the ILC of murines induce deregulated responses in TCD4+ cells 
for commensal bacteria, causing, thus, spontaneous intestinal inflammation [95]. 
In addition, it has been proved that pediatric Crohn’s disease patients have reduced 
levels of MHC II+ ILC3 [96].
The ILC3 have also been described as key effector cells in immunity against 
pathogens [97]. This protector effect occurs mainly through the secretion of IL-22 
and IL-17, which induce epithelial cells and produce antimicrobial peptides against 
pathogens. The lack of ILC3 in the intestine leads to a decrease of IL-22 and hinders 
the production of antimicrobial peptides [88].
However, ILC3 seems to act as a double-edged sword. It was demonstrated that 
inappropriate activation of ILC3 causes intestinal damage through the excessive 
production of IL-22. This may induce epithelial cells and generate chemokines 
which attract neutrophils, which leads to the accumulation of these cells and to the 
tissue destruction [98]. Additionally, it was shown that colonic ILC3 from UC and 
CD patients showed higher expression of IL-22 when compared to healthy individu-
als [99].
Although ILC3 are smaller in number in the gastrointestinal tract, studies on 
ILC1 accumulate in inflamed mucosal tissues. It was shown that the frequency of 
the ILC1 subset was higher in inflamed intestine of CD patients, which indicates a 
role for these IFN-γ-producing ILC1 in the pathogenesis of gut mucosal inflamma-
tion [100, 101]. Forkel et al., also identified an increase in the ILC1 subset frequency 
in DC patients when diagnosed with the disease.
In conclusion, recently, a new population of ILC has been discovered and 
identified as ILCreg. During the intestinal inflammatory process, these cells may 
be induced to suppress the activation of ILC1 and ILC3, through IL-10, resulting in 
protection against the inflammatory process Figure 1 [102].
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